Welcome to our dedicated page for OKYO PHARMA SEC filings (Ticker: OKYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings for OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain, dry eye disease, and ocular inflammatory conditions. As a foreign private issuer, OKYO submits Form 6-K reports under the Securities Exchange Act of 1934, which furnish key company announcements to investors.
Recent 6-K filings referenced in public disclosures include exhibits covering share acquisitions by Panetta Partners Limited, an entity in which OKYO’s Executive Chairman has a beneficial interest, with details on the number of ordinary shares acquired on NASDAQ and updated total holdings. Other 6-Ks furnish announcements about clinical development milestones, such as the registration pathway and planned 100-patient multi-center trial of urcosimod in neuropathic corneal pain, as well as notices of management presentations at industry meetings like the Ophthalmology Innovation Summit and BIO-Europe.
Through Stock Titan, users can access these filings as they are made available from EDGAR and review the attached exhibits that describe OKYO’s clinical progress, regulatory plans, and significant ownership changes. AI-powered summaries help explain the contents of each filing in plain language, highlighting why a particular 6-K may matter for understanding OKYO’s development of urcosimod and its broader ophthalmology strategy.
For investors analyzing OKYO, this filings page offers a structured way to follow its ongoing disclosure record, from clinical trial updates and registration pathway discussions to insider-related share purchases reported via Form 6-K. The combination of real-time access and AI-generated insights can support more efficient review of OKYO’s regulatory communications.
OKYO Pharma reported that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 210,000 of the company’s ordinary shares on NASDAQ. Following this purchase, his total holding is 10,382,677 shares. The news announcement was furnished as Exhibit 99.1 and is not deemed filed under Section 18 of the Exchange Act.
OKYO Pharma LTD has filed a Form 6-K to furnish a news announcement about the regulatory registration pathway and a planned 100-patient multi-center clinical trial of Urcosimod in neuropathic corneal pain. The company states that the announcement, dated September 22, 2025, is included as Exhibit 99.1 to the report. The furnished information is not deemed filed under the Securities Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
OKYO Pharma Limited filed an Amendment No. 1 to its Form 20-F for the fiscal year ended March 31, 2025 to correct an omission in the exhibits. The sole change is a revision of the Exhibit Table to include the Company’s Clawback Policy, which had been erroneously omitted from the original filing. The amendment states that no other disclosures were modified or updated and that subsequent events after the original filing are not reflected.
The filing confirms the registrant is incorporated in Guernsey, prepares financial statements under IFRS, is an emerging growth company, is listed on the NASDAQ Capital Market, and had 37,610,676 ordinary shares outstanding as of July 3, 2025. The company indicates it has filed required reports and submitted required interactive data files.